Gastric Cancer Treatment in China: 2026 Hospital & Cost Guide

Navigating china hospitals as an international patient, however, requires careful planning. From understanding the nuances of D2 lymph node dissections to managing the strict dietary needs of post-gastrectomy recovery in a foreign city, preparation is critical. This guide breaks down the clinical advantages, hospital options, transparent costs, and essential logistics for seeking gastric cancer treatment in China in 2026.

TL;DR: Gastric Cancer Care in China

• Surgical Volume: Top Chinese centers perform thousands of gastrectomies annually, mastering the gold-standard D2 lymph node dissection for improved long-term survival.
• Cost Savings: Comprehensive treatment typically costs 30% to 50% less than in the US, with early-stage endoscopic procedures offering even greater savings.
• Novel Therapies: Patients can access treatments currently unavailable in the West, such as the HER2 ADC RC48 (disitamab vedotin) and CLDN18.2 targeted therapies.
• Care Logistics: Successful medical travel requires remote evaluation, professional medical translation, and securing a serviced apartment with a kitchen for post-operative nutritional management.

International patients travel to China primarily to access high-volume surgical centers that specialize in D2 lymph node dissections and early-stage endoscopic resections, resulting in superior clinical outcomes at a significantly lower cost.

In the field of surgical oncology, there is a proven correlation: high surgical volume equals extensive experience, which in turn leads to better patient survival rates. Because gastric cancer is highly prevalent in East Asia, a single top-tier Chinese cancer center may perform more gastrectomies in one year than several major US hospitals combined.

The standard of care for curable gastric cancer is a radical gastrectomy accompanied by a D2 lymph node dissection. This intricate procedure, which involves removing a specific, extensive network of lymph nodes around the stomach, was pioneered and standardized by East Asian surgeons. High-volume centers in China are globally recognized for their proficiency in performing D2 dissections thoroughly while minimizing post-operative complications.

Beyond surgery, China is at the forefront of pharmaceutical research for gastrointestinal tumors. The country has developed and approved specific targeted therapies and immunotherapies—such as novel antibody-drug conjugates (ADCs) and CAR-T cell therapies—that are highly effective for specific genetic mutations but remain unavailable or strictly limited to clinical trials in North America and Europe.

The leading institutions for gastric cancer in China, such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, offer elite multidisciplinary care, extensive clinical trial access, and dedicated international support.

When evaluating hospital rankings in China, it is important to look beyond general reputation and focus on specialized gastrointestinal oncology departments. The medical landscape is highly centralized, meaning the most complex cases and the latest clinical trials are concentrated in a few elite institutions in Tier 1 cities (Beijing, Shanghai, Guangzhou).

For most international patients requiring complex surgery or advanced systemic therapy, Peking University Cancer Hospital is often the primary destination. However, for standard resections, provincial top-tier (Sanji) hospitals in Tier 2 cities can offer excellent care at a lower price point.

Comprehensive gastric cancer treatment in China generally costs between 30% and 50% of what it would in the United States, offering substantial savings on both advanced surgeries and targeted immunotherapy drugs.

Understanding the financial landscape is a critical part of any China medical consultation. Unlike Chinese citizens who benefit from national health insurance, international patients must pay out-of-pocket. However, because the baseline costs are strictly regulated by the government, the self-pay rates remain highly competitive globally.

For surgical interventions, costs vary by technique and city tier. An early-stage endoscopic resection (ESD/EMR) typically costs between 20,000 and 40,000 RMB. If a full laparoscopic radical gastrectomy is required, patients can expect to pay 80,000 to 130,000 RMB in a Tier 1 city, or 60,000 to 90,000 RMB in a Tier 2 city. Open surgeries are generally slightly less expensive, while robotic-assisted surgeries will incur a premium.

Systemic therapies also present significant savings. Domestic PD-1 inhibitors, which are widely used in combination with chemotherapy for advanced gastric cancer, cost just over 1,000 RMB per dose—a fraction of the price of equivalent drugs in the US. Similar extreme cost differentials apply to other oncology sectors, as detailed in our Lung Cancer Treatment in China: 2026 Drug Price & Care Guide.

Treatment options in China range from stomach-preserving endoscopic resections for early-stage cancer to novel targeted therapies and specialized treatments like HIPEC for advanced stages.

Treatment pathways in China are strictly dictated by the staging of the disease and comprehensive molecular testing. Before any treatment begins, top hospitals will require testing for HER2, PD-L1, MSI-H/dMMR, and Claudin18.2 (CLDN18.2).

For early-stage gastric cancer, Chinese and Japanese hospitals lead the world in Endoscopic Submucosal Dissection (ESD) and Endoscopic Mucosal Resection (EMR). If the tumor is caught early enough and meets specific criteria, surgeons can remove the lesion from the inside of the stomach using an endoscope. This means no incisions, no removal of the stomach organ, and a hospital stay of just a few days.

For locally advanced gastric cancer, the standard protocol involves perioperative chemotherapy (such as FLOT or SOX regimens) to shrink the tumor, followed by a radical gastrectomy with D2 lymph node dissection, and concluding with post-operative chemotherapy.

For advanced or metastatic gastric cancer, the focus shifts to systemic therapy. This is where China's unique pharmaceutical landscape becomes a major advantage, offering a comprehensive gastric cancer targeted therapy guide for patients navigating 2026 drug costs and access. Patients with HER2-positive tumors may access RC48 (disitamab vedotin), a domestically developed antibody-drug conjugate. Furthermore, China is a global leader in clinical trials for CLDN18.2 targeted therapies, including cutting-edge CAR-T cell treatments for solid tumors.

Proper preparation for medical travel to China requires securing a medical visa, arranging professional translation, and booking a serviced apartment with a kitchen to manage the strict post-gastrectomy diet.

Traveling for treatment in China is not just about booking a flight and showing up at a clinic. The administrative and lifestyle logistics require meticulous attention to detail, as outlined in our gastric cancer cost and logistics guide, to ensure patient safety and comfort.

The first step should always be a remote evaluation. Before committing to travel, patients should submit their pathology reports, DICOM imaging, and molecular test results to a target hospital. This allows the medical team to confirm if the patient is a candidate for surgery or specific therapies, providing a preliminary treatment plan and cost estimate with zero travel risk.

Once travel is confirmed, accommodation becomes the next critical decision. Unlike many other procedures, gastric cancer surgery fundamentally alters how a patient digests food. Post-operative patients must consume small, frequent, highly controlled, and easily digestible meals to recover safely and avoid "dumping syndrome" (rapid gastric emptying). Relying on hotel room service or local restaurants is unsafe. Therefore, booking a serviced apartment with a full kitchen near the hospital is mandatory, allowing family members or hired caregivers to prepare appropriate nutritional meals.

Additionally, navigating the top 10 hospitals in China requires overcoming significant language barriers. While international departments offer English services, the core surgical and oncology wards operate entirely in Mandarin. Hiring a professional, medically trained bilingual care coordinator ensures that informed consent, daily doctor rounds, and nursing instructions are perfectly understood.

The primary risks of international medical travel for gastric cancer include gaps in post-operative care continuity and regulatory differences in drug approvals, which must be mitigated with complete, translated medical records.

While the surgical and financial benefits of seeking care in China are substantial, Ask China Medical emphasizes that cross-border healthcare carries inherent logistical risks that must be mitigated before departure.

The most significant risk is the continuity of care upon returning home. A gastrectomy requires lifelong nutritional monitoring. Patients must have their Vitamin B12, iron levels, and overall body weight tracked regularly by a local physician. If a patient returns to their home country without a clear, translated post-operative care plan, local doctors may struggle to provide appropriate follow-up care.

Furthermore, there is the issue of pharmaceutical continuity. If a patient begins a systemic treatment regimen in China using a domestically developed drug (like RC48 or specific PD-1 inhibitors), they must verify if that exact medication—or an acceptable FDA/EMA-approved alternative—is available in their home country. If not, the patient may be forced to switch therapies mid-treatment or travel back to China for ongoing infusions.

To prevent these issues, patients must insist on receiving comprehensive documentation before leaving the Chinese hospital. This includes the full surgical record, pathology slides, molecular testing reports, DICOM imaging files, and a detailed, English-translated discharge summary outlining the recommended ongoing care. Similar documentation standards are vital across all oncological disciplines, as noted in our Ovarian Cancer Treatment in China: 2026 Cost & Care Guide.

Ask China Medical provides the professional guidance and logistical support necessary to help you safely and seamlessly navigate your gastric cancer treatment journey in China.

Navigating international healthcare requires precise information, clear logistical planning, and professional support. You do not have to manage the complexities of hospital selection, medical translation, and cross-border care continuity alone.

Our team provides professional guidance to help you understand your medical care options in China. We assist with organizing your medical records, securing remote second opinions from top-tier oncology centers, and managing the practical details of your medical journey so you can focus entirely on treatment and recovery.

Ready to explore your options? Start your consultation with Ask China Medical today to ensure your next steps are safe, informed, and seamlessly coordinated.